CYP3A4 and breast cancer: We found that women who received cyclophosphamide-based adjuvant chemotherapy for breast cancer and had the CYP3A4 *1B*/*1A genotype had significantly worse DFS than those who were CYP3A4 *1A/*1A wild-type (HR 2.44, 95% CI 1.52, 5.14).